Frank, M., Qualls, D., Ghobadi, A., Gauthier, J., Tees, M., Mountjoy, L., McGuirk, J., Neelapu, S., Karmali, R., Isufi, I., Hill, B., Sauter, C., Diefenbach, C., Spiegel, J., Bachier-Rodriguez, L., Ghosh, M., Shah, N., Lakhotia, R., Hernandez-Ilizaliturri, F., Abhyankar, A., Chong, E., Schwede, M., Patel, K., Oluwole, O., Baird, J., Denlinger, N., Awan, F., Jain, M., Timmerman, J., Sanchez, C., Kumaran, M., Yared, J., Arnason, J., Tatake, I., Gergis, U., Riedell, P., Pratz, K., Shah, N. (2025). Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial). Blood. https://doi.org/10.1182/blood-2025-667